Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06704971 · ClinicalTrials.gov registry record

Assessing Cognitive Decline at Home

A clinical trial of Mild Cognitive Impairment and Dementia, sponsored by Stanford University.

Recruiting
Registry status
25
Enrollment target
1
Study location

NCT06704971: Recruiting study of Mild Cognitive Impairment and Dementia, sponsored by Stanford University.

NCT06704971 is a study of Mild Cognitive Impairment and Dementia that is actively recruiting participants, run by Stanford University. The registered enrollment target is 25 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06704971, a study of Mild Cognitive Impairment and Dementia, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
25 participants
Enrollment target
1
Study location

Study Summary

Neuropsychiatric symptoms (NPS) refer to a range of mental and emotional issues that can be observed through how patients move, perform daily tasks, and express feelings on their faces. In this study, the investigators want to find ways to accurately and unobtrusively track these symptoms in people's homes over time. Our goals are to note when these symptoms happen, predict potential problems, and gather clear data to help doctors make accurate diagnoses. To do this, the investigators will first collect information from participants who have in-home sensors. the investigators will then use special computer programs that can recognize everyday activities and identify features that connect to scores from the Mild Behavioral Impairment Checklist (MBI-C). These scores will be compared to a questionnaire (NPIQ) filled out by caregivers or family members, along with any relevant information from doctors about the patients' symptoms. The investigators aim to see how these features can help differentiate between types of NPS, such as mood changes and agitation. Finally, the investigators will create a dashboard for doctors that summarizes the patterns of these symptoms in patients, making it easier to monitor and manage their mental health.

Primary Outcome

Assessing NPS relies primarily on clinician observation \& interviews with caregivers, usually within brief \& infrequent clinical visits. Precise assessment and monitoring methods would incorporate objective, patient- \& caregiver-friendly, real-time tools and provide reliable \& frequently captured data. We aim to create a system that can monitoring individual and subsyndromes of NPS; and detect early changes in NPS by automatically quantifying \& detecting relevant behavioral abnormalities ba

Study Locations (1)

California

  • Clinical Excellence Research Center - Palo Alto

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2024-10-01
Est. Completion 2026-12-30
Stanford University

1,744 total trials

What NCT06704971 shows while recruiting

NCT06704971 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (98% lower).

The record links to 6 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.

NCT06704971 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06704971 about?

NCT06704971 is a clinical study titled "Assessing Cognitive Decline at Home". Neuropsychiatric symptoms (NPS) refer to a range of mental and emotional issues that can be observed through how patients move, perform daily tasks, and express feelings on their faces. In this study, the investigators want to find ways to accurately and unobtrusively track these symptoms in people'...

What is the current status of trial NCT06704971?

This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2024-10-01. Estimated completion is 2026-12-30.

What conditions does trial NCT06704971 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment, Dementia, Memory Impairment, Dementia Alzheimers, Mild Dementia.

Who is sponsoring clinical trial NCT06704971?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06704971 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mild Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06704971's enrollment target sits among peer trials

25 172nd of 205 higher than 34 of 205 other Mild Cognitive Impairment trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06704971, the US trial registry maintained by the National Library of Medicine. NCT06704971 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.